Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens

scientific article

Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2012PLoSO...748524P
P356DOI10.1371/JOURNAL.PONE.0048524
P932PMC publication ID3485360
P698PubMed publication ID23119046
P5875ResearchGate publication ID232766830

P50authorBeatriz PerdigueroQ112248161
Jose Luis NájeraQ114406498
Rubén González-SanzQ114406499
Mariano EstebanQ30004051
Carlos Oscar Sanchez SorzanoQ56027899
Thierry CalandraQ56616768
Giuseppe PantaleoQ88061163
Thierry RogerQ40228404
Carmen E GómezQ42100464
P2093author name stringJulie Delaloye
Victoria Jiménez
P2860cites workA candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responsesQ21135240
Viruses and ApoptosisQ22255620
Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosisQ24302248
The vaccinia virus protein F1L interacts with Bim and inhibits activation of the pro-apoptotic protein BaxQ24310440
Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligandsQ24321449
Susceptibility of different leukocyte cell types to Vaccinia virus infectionQ24801903
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletionsQ27320923
Dendritic cells and the control of immunityQ27860918
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosisQ28292299
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasomeQ28389050
Viral control of mitochondrial apoptosisQ28472776
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectorsQ28742751
Improved NYVAC-based vaccine vectorsQ28742982
The BCL-2 protein family: opposing activities that mediate cell deathQ29547380
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandQ29547531
The biochemistry of apoptosisQ29547741
Molecular mechanisms of caspase regulation during apoptosisQ29617861
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccineQ30977303
Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).Q33320536
Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivoQ33328336
Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigensQ33627613
Vaccinia virus protein F1L is a caspase-9 inhibitorQ33648434
Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosisQ33717065
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateQ33749950
Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptorQ33912043
Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individualsQ33916776
Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-β-dependent induction of pro-apoptotic Noxa.Q33941041
Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genesQ33962664
Cross-presentation in viral immunity and self-tolerance.Q34119651
Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding proteinQ34182371
Immunology 102 at poxvirus U: avoiding apoptosis.Q34209976
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.Q34247289
Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cellsQ34332462
The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxvirusesQ34469355
Induction of immunity to human immunodeficiency virus type-1 by vaccinationQ34540645
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesQ34772727
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccineQ35009558
Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.Q35024193
Structural determinants of caspase-9 inhibition by the vaccinia virus protein, F1LQ35182960
Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen deliveryQ35551800
Ways of dying: multiple pathways to apoptosis.Q35560936
Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in miceQ35943846
Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cellsQ45734461
Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cellsQ45736403
Quantification of antigen specific CD8+ T cells using an ELISPOT assayQ47999428
Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.Q51968415
CD8+ T-cell responses to different HIV proteins have discordant associations with viral loadQ57259602
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade CQ79561534
Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responsesQ80445239
Lead and follow: the dance of the dendritic cell and T cellQ81020106
Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.Q36315031
Near death experiences: poxvirus regulation of apoptotic deathQ36346832
Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentationQ36376037
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus AnkaraQ36692389
Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selectionQ37248017
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challengeQ37287080
Nonreplicating vaccinia vector efficiently expresses recombinant genesQ37299518
Viral inhibitors reveal overlapping themes in regulation of cell death and innate immunityQ37592685
Poxvirus vector-based HIV vaccinesQ37803318
MVA and NYVAC as vaccines against emergent infectious diseases and cancer.Q37859845
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).Q38484762
The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.Q38725610
The vaccinia virus-encoded Bcl-2 homologues do not act as direct Bax inhibitorsQ39455647
Vaccinia virus F1L interacts with Bak using highly divergent Bcl-2 homology domains and replaces the function of Mcl-1.Q39539847
Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccineQ39589039
The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activationQ39611834
Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse modelQ39790409
Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expressionQ39897867
The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protectionQ40390611
Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus AnkaraQ40506182
Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptorsQ40542008
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypoxQ40579847
Vaccinia virus F1L protein is a tail-anchored protein that functions at the mitochondria to inhibit apoptosisQ40722650
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLsQ41057373
Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell lineQ41076591
Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulenceQ41684943
Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primatesQ42100401
Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7.Q42702068
Isolation of mouse peritoneal cavity cellsQ42858996
Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and celluQ43456447
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteersQ44590524
Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.Q45235855
Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells.Q45369720
The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunityQ45411290
Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicityQ45418101
The vaccinia virus N1L protein influences cytokine secretion in vitro after infectionQ45421140
Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy.Q45421530
Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosisQ45437312
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humansQ45723463
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectapoptotic processQ14599311
HIV/AIDSQ12199
P304page(s)e48524
P577publication date2012-10-31
P1433published inPLOS OneQ564954
P1476titleDeletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens
P478volume7

Reverse relations

cites work (P2860)
Q37209483Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants
Q47552501Characterizing the effects of insertion of a 5.2 kb region of a VACV genome, which contains known immune evasion genes, on MVA immunogenicity
Q38156198Clinical applications of attenuated MVA poxvirus strain.
Q36947039Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.
Q92716321Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy
Q35656345Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity
Q89633807Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
Q37643731Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
Q27306437Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C
Q27321985Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection
Q33602820Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses
Q47233214E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox
Q36978452Enhancing poxvirus vectors vaccine immunogenicity.
Q40339467HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci
Q45325213Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
Q40843765Illuminating inflammasome activity in vivo.
Q47252143Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways
Q40071705Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models
Q34796206Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways
Q50533334Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.
Q90434144Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses
Q36980878Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.
Q36192765Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
Q33870595Structure of vaccinia virus A46, an inhibitor of TLR4 signaling pathway, shows the conformation of VIPER motif
Q56556724The Gene of Goatpox Virus Encodes an Inhibitor of NF-κB and Apoptosis and May Serve as an Improved Insertion Site To Generate Vectored Live Vaccine
Q26995905The evolution of poxvirus vaccines
Q103027729Viral Bcl2s' transmembrane domain interact with host Bcl2 proteins to control cellular apoptosis
Q34991112Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.

Search more.